Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 60460 | 3.345 |
09:34 ET | 60030 | 3.335 |
09:36 ET | 81491 | 3.305 |
09:38 ET | 11478 | 3.2774 |
09:39 ET | 23633 | 3.2563 |
09:41 ET | 43915 | 3.24 |
09:43 ET | 57620 | 3.255 |
09:45 ET | 20502 | 3.255 |
09:48 ET | 26863 | 3.2692 |
09:50 ET | 59644 | 3.275 |
09:52 ET | 31193 | 3.295 |
09:54 ET | 14212 | 3.295 |
09:56 ET | 6856 | 3.3 |
09:57 ET | 6538 | 3.28 |
09:59 ET | 18850 | 3.28 |
10:01 ET | 5145 | 3.265 |
10:03 ET | 30052 | 3.255 |
10:06 ET | 3508 | 3.25 |
10:08 ET | 17564 | 3.2692 |
10:10 ET | 20203 | 3.257 |
10:12 ET | 25926 | 3.25 |
10:14 ET | 26159 | 3.255 |
10:15 ET | 40563 | 3.265 |
10:17 ET | 3422 | 3.265 |
10:19 ET | 100644 | 3.265 |
10:21 ET | 5160 | 3.265 |
10:24 ET | 21410 | 3.265 |
10:26 ET | 77772 | 3.27 |
10:28 ET | 52377 | 3.255 |
10:30 ET | 1748 | 3.2585 |
10:32 ET | 800 | 3.25 |
10:33 ET | 32520 | 3.24 |
10:35 ET | 80280 | 3.255 |
10:37 ET | 17610 | 3.26 |
10:39 ET | 104824 | 3.24 |
10:42 ET | 84948 | 3.255 |
10:44 ET | 182330 | 3.265 |
10:46 ET | 4500 | 3.265 |
10:48 ET | 63439 | 3.27 |
10:50 ET | 30841 | 3.265 |
10:51 ET | 2471 | 3.2688 |
10:53 ET | 2423 | 3.26 |
10:55 ET | 2449 | 3.26 |
10:57 ET | 66684 | 3.255 |
11:00 ET | 4841 | 3.255 |
11:02 ET | 36214 | 3.265 |
11:04 ET | 4050 | 3.26 |
11:06 ET | 59818 | 3.26 |
11:08 ET | 900 | 3.26 |
11:09 ET | 57567 | 3.265 |
11:11 ET | 3300 | 3.2601 |
11:13 ET | 10100 | 3.265 |
11:15 ET | 3070 | 3.2621 |
11:18 ET | 83012 | 3.2887 |
11:20 ET | 13410 | 3.29 |
11:22 ET | 14618 | 3.3 |
11:24 ET | 14408 | 3.31 |
11:26 ET | 3200 | 3.305 |
11:27 ET | 43867 | 3.315 |
11:29 ET | 2981 | 3.32 |
11:31 ET | 21479 | 3.325 |
11:33 ET | 26727 | 3.325 |
11:36 ET | 26894 | 3.315 |
11:38 ET | 47840 | 3.305 |
11:40 ET | 18684 | 3.315 |
11:42 ET | 500 | 3.315 |
11:44 ET | 1800 | 3.315 |
11:45 ET | 16500 | 3.31 |
11:47 ET | 110332 | 3.31 |
11:49 ET | 3205 | 3.32 |
11:51 ET | 68981 | 3.335 |
11:54 ET | 7455 | 3.335 |
11:56 ET | 8367 | 3.335 |
11:58 ET | 3573 | 3.34 |
12:00 ET | 1900 | 3.34 |
12:02 ET | 43123 | 3.355 |
12:03 ET | 7504 | 3.355 |
12:05 ET | 26802 | 3.35 |
12:07 ET | 36958 | 3.365 |
12:09 ET | 6004 | 3.36 |
12:12 ET | 964 | 3.365 |
12:14 ET | 1700 | 3.365 |
12:16 ET | 400 | 3.365 |
12:18 ET | 1020 | 3.365 |
12:20 ET | 48583 | 3.3668 |
12:21 ET | 988 | 3.37 |
12:23 ET | 2280 | 3.37 |
12:25 ET | 44755 | 3.355 |
12:27 ET | 54419 | 3.38 |
12:30 ET | 52745 | 3.375 |
12:32 ET | 8373 | 3.375 |
12:34 ET | 18463 | 3.375 |
12:36 ET | 77962 | 3.36 |
12:38 ET | 20563 | 3.36 |
12:39 ET | 5900 | 3.36 |
12:41 ET | 50782 | 3.375 |
12:43 ET | 5426 | 3.3797 |
12:45 ET | 5280 | 3.38 |
12:48 ET | 172947 | 3.36 |
12:50 ET | 7552 | 3.36 |
12:52 ET | 79220 | 3.36 |
12:54 ET | 16060 | 3.36 |
12:56 ET | 36624 | 3.355 |
12:57 ET | 36988 | 3.365 |
12:59 ET | 1500 | 3.365 |
01:01 ET | 22946 | 3.36 |
01:03 ET | 10792 | 3.37 |
01:06 ET | 41388 | 3.365 |
01:08 ET | 105726 | 3.37 |
01:10 ET | 1900 | 3.375 |
01:12 ET | 26823 | 3.37 |
01:14 ET | 2027 | 3.375 |
01:15 ET | 28084 | 3.385 |
01:17 ET | 18867 | 3.395 |
01:19 ET | 94229 | 3.4 |
01:21 ET | 35248 | 3.405 |
01:24 ET | 5092 | 3.405 |
01:26 ET | 47400 | 3.41 |
01:28 ET | 6880 | 3.405 |
01:30 ET | 4200 | 3.405 |
01:32 ET | 30382 | 3.42 |
01:33 ET | 35716 | 3.415 |
01:35 ET | 10913 | 3.4199 |
01:37 ET | 4342 | 3.42 |
01:39 ET | 3047 | 3.415 |
01:42 ET | 3969 | 3.42 |
01:44 ET | 730 | 3.42 |
01:46 ET | 90414 | 3.4046 |
01:48 ET | 2440 | 3.405 |
01:50 ET | 1300 | 3.4067 |
01:51 ET | 6634 | 3.407 |
01:53 ET | 1700 | 3.41 |
01:55 ET | 2766 | 3.41 |
01:57 ET | 20218 | 3.42 |
02:00 ET | 1185 | 3.42 |
02:02 ET | 9128 | 3.41 |
02:04 ET | 52447 | 3.425 |
02:06 ET | 4008 | 3.43 |
02:08 ET | 2589 | 3.425 |
02:09 ET | 25781 | 3.43 |
02:11 ET | 35435 | 3.425 |
02:13 ET | 24539 | 3.41 |
02:15 ET | 5827 | 3.4123 |
02:18 ET | 122528 | 3.43 |
02:20 ET | 8672 | 3.4354 |
02:22 ET | 8383 | 3.44 |
02:24 ET | 6021 | 3.4321 |
02:26 ET | 9864 | 3.45 |
02:27 ET | 11434 | 3.455 |
02:29 ET | 16296 | 3.46 |
02:31 ET | 119594 | 3.45 |
02:33 ET | 9969 | 3.4582 |
02:36 ET | 6200 | 3.455 |
02:38 ET | 41572 | 3.46 |
02:40 ET | 13880 | 3.455 |
02:42 ET | 3302 | 3.455 |
02:44 ET | 2090 | 3.455 |
02:45 ET | 2379 | 3.46 |
02:47 ET | 4402 | 3.46 |
02:49 ET | 219920 | 3.4321 |
02:51 ET | 6473 | 3.43 |
02:54 ET | 45746 | 3.425 |
02:56 ET | 37102 | 3.43 |
02:58 ET | 21007 | 3.4281 |
03:00 ET | 2495 | 3.425 |
03:02 ET | 2350 | 3.42 |
03:03 ET | 57505 | 3.415 |
03:05 ET | 110722 | 3.45 |
03:07 ET | 12663 | 3.455 |
03:09 ET | 26840 | 3.45 |
03:12 ET | 18251 | 3.455 |
03:14 ET | 1643 | 3.455 |
03:16 ET | 40615 | 3.445 |
03:18 ET | 1096 | 3.4499 |
03:20 ET | 13154 | 3.44 |
03:21 ET | 57035 | 3.43 |
03:23 ET | 21176 | 3.43 |
03:25 ET | 97200 | 3.435 |
03:27 ET | 894 | 3.435 |
03:30 ET | 9903 | 3.44 |
03:32 ET | 5431 | 3.435 |
03:34 ET | 38852 | 3.435 |
03:36 ET | 40594 | 3.445 |
03:38 ET | 85955 | 3.43 |
03:39 ET | 42511 | 3.42 |
03:41 ET | 30547 | 3.425 |
03:43 ET | 41154 | 3.425 |
03:45 ET | 21019 | 3.425 |
03:48 ET | 24249 | 3.425 |
03:50 ET | 92168 | 3.425 |
03:52 ET | 192638 | 3.43 |
03:54 ET | 54278 | 3.445 |
03:56 ET | 338116 | 3.465 |
03:57 ET | 89895 | 3.47 |
03:59 ET | 1250942 | 3.47 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.0B | -10.0x | --- |
Vera Therapeutics Inc | 2.0B | -18.1x | --- |
Summit Therapeutics Inc | 2.1B | -65.9x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.5x | --- |
Fusion Pharmaceuticals Inc | 1.8B | -15.2x | --- |
CG Oncology Inc | 2.2B | -30.4x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.41 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -10.0x |
Price/Sales (TTM) | 3,786.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.